Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

US Market Report for Ankylosing Spondylitis Immunology Drugs 2018 - Research and Markets

Research and Markets
Posted on: 02 Nov 17

The "US Market Report for Ankylosing Spondylitis Immunology Drugs 2018 - MedCore" report has been added to Research and Markets' offering.

Treatment options for the AS include medication, exercise, physical therapy and others. In severe cases posture correcting surgery may also be an option. The medication treatment includes nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, naproxen, and aspirin. If NSAIDs alone do not control inflammation, it may require an injection of corticosteroids directly into the affected joints to bring quick but temporary relief. An injection may be given to the sacroiliac, hip, knee joint, but it is not given in the spine.

In moderate to severe cases the treatment involves disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (Rheumatrex). Steroid injections into the joint or tendon may be helpful in some cases. Another option includes biologics, such as HUMIRA (adalimumab), Amjevita and Imraldi (biosimilars to HUMIRA), CIMZIA (certolizumab pegol), Enbrel (etanercept), Erelzi and Benepali (biosimilars to Enbrel), SIMPONI (golimumab), REMICADE (infliximab), Inflectra and Flixabi (biosimilars to REMICADE), Renflexis (infliximab-abda) and Cosentyx (secukinumab). Some of these DMARDs may be used for the treatment of ankylosing spondylitis as well as for other immune disorders, such as psoriasis, rheumatoid arthritis, Crohn's disease, ulcerative colitis and others.

Key Topics Covered:

Executive Summary

1. Version History

2. 9-Step Methodology

3. Mechanism of Action

3.1 Introduction

3.1.1 Tumor Necrosis Factor (Tnf)

3.1.2 B-Cell Inhibitors

3.1.3 Interleukin Inhibitors

3.1.4 Janus Kinase Inhibitors

3.1.5 Co-Stimulation Modulators

4. Product Assessment

4.1 Key Marketed Products

4.2 Key Products in Pipeline

4.2.1 Barcitinb (Olumiant)

4.2.2 Guselkumab (Tremfya)

4.2.3 Cobitolimod (Kappaproct)

4.2.4 Mavrilimumab

4.2.5 Sirukumab

4.2.6 Vobarilizumab

4.3 Products in Development By Core Companies

4.4 Clinical Trial By Disease

5. Country Profile

5.1 United States

5.1.1 Population And Demographics

5.1.2 Treatment Size Analysis for 2017

5.1.3 Drug Cost Analysis

6. Ankylosing Spondylitis Market

6.1 Introduction

6.1.1 Causes And Disease Progression

6.1.2 Diagnosis And Treatment Options

6.1.3 Symptoms And Complications

6.1.4 Epidemiology

6.2 Market Overview

6.3 Trend Analysis

6.4 Competitive Analysis

Companies Mentioned

  • AbbVie Inc.
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceuticals
  • UCB S.A.

For more information about this report visit

View source version on

Business Wire

Last updated on: 02/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.